• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    PetVivo Reports Fiscal Q1 2026 Results

    8/14/25 4:40:00 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care
    Get the next $PETV alert in real time by email

    MINNEAPOLIS, MN, US, Aug. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., including its wholly-owned subsidiary Petvivo Animal Health, Inc. (OTCQX:PETV, OTC ID: PETVW)), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, reported results for its first quarter of fiscal year 2026 ended June 30, 2025. All comparisons are to the previous year first quarter period ending June 30, 2024, unless otherwise noted.

    The company will hold a conference call today, August 14, 2025, at 5:00 p.m. Eastern time to discuss the results for the quarter, followed by a question-and-answer session (see dial-in information below).

    Fiscal Q1 Financial Highlights

    • Revenues increased totaled $298,000, an increase of 141% compared to the same year-ago quarter. The increase is due to product line expansion with our Precise PRRP line, which is administered alongside our Spring® product, and expansion of our in-house sale force and distributor channel. These factors helped drive the continued expansion of the company's addressable market from the large equine market into the larger and faster-growing companion animal market.
    • National distributor network sales increased 192% to $198,000 or 67% of total revenues.
    • Gross profit increased 69% to $187,000, with gross margin of 63%.
    • Operating loss decreased 9% to $1.8 million, with the improvement due to the company's strategic corporate restructuring and cost reduction program implemented in the last fiscal year, along with increased sales of new products.
    • Net loss increased 13% to $2.3 million or $(0.09) per basic and diluted share due to increase in certain non-cash expenses compared to (0.11) per basic and diluted in the last fiscal year quarterly period.
    • Cash totaled $3.3 million on June 30, 2025, compared to $228,000 on March 31, 2025, with the increase primarily due to net proceeds of $4.7 million received from financing activities during the quarter.
    • Total liabilities decreased 39% to $3.1 million, primarily due to the termination of a ten-year lease of our second manufacturing facility and also the extinguishment of derivative liabilities with our convertible notes, due to the modification of the convertible note terms.

    Fiscal Q1 Operational Highlights

    • Signed definitive distribution agreement with Eq Especialidades to inventory, market and promote Spryng™ throughout Mexico, representing the company's first entrance into the international market. Initial shipments to veterinary clinics in Mexico have begun.
    • Established a strategic partnership with PiezoBioMembrane, a pioneer in biodegradable piezoelectric materials intended for implantable applications, to advance research and development of revolutionary functional biomaterials that promote regeneration, restoration and/or remodeling of damaged or injured tissue and bone in animals and humans. The collaboration is currently nearing completion of Phase 1 of the three-phase joint research and development project to determine that materials from both partners' products can be combined into a single offering to provide therapeutic benefits to animals and humans.
    • Advanced the company's transformative strategic alliance with Digital Landia, a pioneer in Agentic artificial intelligence (AI) solutions. The collaboration centers Digital Landia's revolutionary AI technology that deciphers, at 97% accuracy, equine and companion animal behavior and communication through real-time analysis of vocalizations, body language, and physiological signals captured via a smartphone camera. The advanced AI-powered technology has been integrated with PetVivo's veterinary products in a first-of-kind global pet care ecosystem. Beta testing is currently underway, with official commercial launch planned for the company's fiscal third quarter.
    • Continued to ramp up sales and marketing into the animal market for the commercialization of PrecisePRP, a proprietary and revolutionary allogeneic platelet rich plasma (PRP) product for horses and dogs developed. Sold under a new exclusive licensing and supply agreement with VetStem signed last quarter, the product has been receiving favorable reports from veterinarians regarding the ease-of-use of this regenerative product.
    • Entered new strategic collaboration with Commonwealth Markets, the syndicated ownership group behind the 2023 Kentucky Derby winner. Commonwealth will integrate Spryng® and Precise PRP into the care protocols of its top-tier thoroughbred stable. These products will be used as a preventative measure and as a management solution to promote joint health, extend performance longevity, and support recovery in high-impact training and racing environments.
    • Closed the remaining $4.4 million purchase option as part of a private placement offering initiated in March 2025 totaling $5 million in equity financing in exchange for five million shares of the company's Series B convertible preferred stock.

    Subsequent Events

    • Uplisted the trading of the company's common stock from the OTC Markets' OTCQB® Venture Market to its highest-level tier, the OTCQX Best Market. To qualify for the OTCQX, public companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market marks an important milestone, demonstrating the company's qualifications as may be required for institutional investors, as well as building visibility among retail investors.

    • Exhibited at the Texas Equine Veterinary Association 2025 Summer CE Symposium held on July 3 - August 2, in Marble Falls, Texas. PetVivo demonstrated its SPRYNG® with OsteoCushion® Technology, an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. Also exhibited and spoke at other smaller industry events during the quarter, demonstrating the research-backed benefits of Spryng to veterinarians, including leading sports medicine and rehabilitation experts in the veterinary industry. The events have helped to drive greater adoption of Spryng by expanding awareness among key decision-makers of its effectiveness and benefits in the management of osteoarthritis in animals.

    Management Commentary

    "Our growth momentum continued into the first quarter as we expanded the use of our lead animal osteoarthritis veterinary medical device, Spryng® with OsteoCushion® Technology," commented PetVivo CEO, John Lai. "We also advanced the development and use of technologies we've gained from new major partnerships that we formed earlier this year.

    "These partnerships have provided innovative technologies that involve diagnostics and medical treatments which have been transformative for our platform, and for the veterinarians and pet owners that we serve.

    "Since introduction of Spryng® in late 2021, this flagship product has now been used by more than 1,000 veterinary clinics across all 50 states. Now with the recent addition of our first distributor in Mexico, we can include several new international clinics as well.

    "Mexico is a very attractive market for our animal health solutions, especially given how the country's veterinary healthcare market is expected to grow at a compounded annual growth rate of 11 percent to reach $2.4 billion by 2031. Personal horse ownership is deeply intertwined with Mexican culture and tradition, which makes the Mexican marketplace exceptionally ideal for us.

    "As those sales begin to ramp up in Mexico, our U.S. national distributor network sales increased their sales by 192% compared to the year-ago quarter, reaching $198,000 or 67% of total revenue. The growth in distributor sales, combined with the expansion of our in-house sales force and product offerings, drove a more than 140% increase in total revenue for the quarter, reaching nearly $300,000, making it one of our best quarters, to date.

    "This performance also reflects the success of our marketing efforts, which is still strongly focused on the large equine market as we further expand into the larger and faster-growing companion animal market.

    "The growth also reflects the success of the several new highly experienced territory managers we have deployed nationwide over the past year, as well the addition of the new team of professional sales representatives and technical service veterinarians we've engaged to support them. Together, they have been developing relationships with the nation's leading veterinary clinics, veterinary corporate entities, consolidators and distributors to support future sales.

    "These efforts have been driving the greater adoption of Spryng® as well as increasing the awareness and acceptance of PrecisePRP for the treatment of osteoarthritis in animals. We've continued to focus on expanding awareness of the benefits of both of these innovative products among key decision-makers.

    "The commercialization of Spryng® and PrecisePRP has been receiving very favorable reports from veterinarians regarding the ease-of-use for each of these products and their effectiveness in the management of osteoarthritis in horses and companion animals.

    "We've also been advancing our strategic alliance with Digital Landia, a pioneer in Agentic AI solutions. Our collaboration with Digital Landia centers on their Pet Artificial Intelligence technology. This technology represents a paradigm shift in how we understand pets and their physical health. By aligning our clinically proven therapies with this AI technology, we believe PetVivo is uniquely positioned at the intersection of AI innovation and veterinary care.

    "We anticipate Pet AI to rival mainstream AI applications in terms of adoption rates and thereby create tremendous visibility for our brands. Advanced technology is currently being integrated with our veterinary products to create a first-of-kind global pet care ecosystem. Beta testing is underway and advancing well, and we anticipate the official commercial launch to take place in our third fiscal quarter.

    "The cross pollination of these two new technologies is creating an exciting new future for PetVivo, one that we believe will be transformative for not only us but also for veterinarians and their many precious patients.

    "In June, we announced a strategic collaboration with Commonwealth Markets, the syndicated ownership group who was behind 2023 Kentucky Derby winner, Mage, and the 2022 Dubai World Cup Champion named Country Grammer. Our partnership with Commonwealth has been centered on the clinical use and promotion of SPRYNG® with OsteoCushion® Technology and Precise PRP.

    "As part of our collaboration, Commonwealth has integrated SPRYNG® and PrecisePRP into the care protocols of a number of their top-tier thoroughbred stables. In this environment, they are using these technologies as both a preventative measure and/or a management solution to promote joint health and extend performance longevity.

    "In addition to this clinical implementation, we are exploring co-branded content, educational initiatives, and industry outreach to elevate awareness around joint wellness and to support the broader adoption of SPRYNG® and PrecisePRP across the equine health community. This unique partnership with Commonwealth, a recognized leader at the highest levels of the sport, marks a major advancement for both SPRYNG® and PrecisePRP.

    "By combining our clinical expertise and commercial capabilities with Commonwealth's equine industry knowledge and vast network, we can provide veterinarians with cutting-edge, effective solutions that enhance recovery and long-term soundness in competitive horses.

    "During the first fiscal quarter we also established a strategic partnership with PiezoBioMembrane, a pioneer in biodegradable piezoelectric materials for use in implantable applications. Through our collaboration, we are looking to advance the research and development of revolutionary functional biomaterials that can promote regeneration, restoration and/or remodeling of damaged or injured tissue and bone in both animals and humans.

    "We are currently nearing completion of Phase 1 of our three-phase joint research and development project, which is designed to determine if materials from our mutual products can be combined into a single offering.

    "Altogether, our latest new technologies have created an exciting future for PetVivo that we believe will be transformative to not only veterinarians and the patients they serve, but potentially for humans as well.

    "We expect to see continued strong sales momentum and market penetration for the duration of fiscal 2026 and beyond. In fact, we have never been in a better position to accelerate our growth and expand across high growth markets.

    "The U.S. animal health market is expected to double to $11.3 billion by 2030. Such massive growth is rare for such an already large industry, and it provides us amazing tailwinds.

    "As we continue to grow and expand, we will remain committed to advancing the best in pet health solutions and ensuring our products reach more veterinary professionals and pet owners, and this driving greater value for our stakeholders."

    Fiscal Q1 2026 Financial Summary

    Revenues for fiscal first quarter ending June 30, 2025, increased 141% to a $297,500, with growth due to additional product offering expansion, continue expansion from the large equine market into the larger and faster-growing companion animal market, as well as expansion of the company's sales force and nationwide distributor network. Distributor sales increased 192% to $198,380 or 67% of total revenues.

    Gross profit totaled $187,000 or 63% of revenues, an increase of 69% compared to $111,000 or 89.5% of revenues in the same year-ago quarter. The decrease in gross margin was due to a new change in product sales mix.

    Operating expenses decreased 9% to $2.0 million from $2.2 million in the year-ago quarter. The reduction was due to a strategic company-wide cost reduction and restructuring program the company implemented during the previous fiscal year.

    Net loss available to common stockholders totaled $2.3 million or $(0.09) per basic and diluted share, improving 15% from a net loss of $2.0 million or $(0.11) per basic and diluted share in the year-ago quarter.

    Net cash used in operating activities increased to $1.6 million from $1.5 million in the same year-ago period, which was primarily due to one-time lease termination expenses and an increase with our inventory purchase with our new Precise PRP product line.

    Cash totaled $3.3 million on June 30, 2025, compared to $228,000 on March 31, 2025, with the increase primary due to the net proceeds of $4.7 million received from financing activities during the quarter.

    Total liabilities decreased 39% to $3.1 million, primarily due to the termination of a ten-year lease of our second manufacturing facility and also the extinguishment of derivative liabilities with our convertible notes, due to the modification of the convertible note terms.

    For a more detailed overview of the company's financials, see the consolidated statements of operations and consolidated balance sheet below.

    Fiscal 2026 Outlook

    For the full fiscal year ending March 31, 2026, the company anticipates another year of record growth and improving bottom line as it continues to expand the use of Spryng® with OsteoCushion® Technology as well as other new products offered by its expanded medical therapeutics platform.

    Conference Call

    PetVivo management will host a conference call later today to discuss these results, which will include a question-and-answer period.



    Date: Thursday, August 14, 2025

    Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)

    Toll-free dial-in number: +1 253 205 0468

    Conference ID: 89205449838

    Passcode: 680979

    Webcast (live and replay): click here.

    A replay of the webcast will be available through the same link following the conference call.

    The conference call webcast is also available via a link in the Investors section of the company's website at petvivo.com/investors.

    About PetVivo Holdings

    PetVivo Holdings Inc., and its wholly-owned subsidiary Petvivo Animal Health, Inc. (OTCQX:PETV, OTCID: PETVW)) is an emerging biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

    PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of 12 patents protects the company's biomaterials, products, production processes and methods of use. The company's lead products SPRYNG® with OsteoCushion® technology, is a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses. It also offers PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians. Both are currently available for commercial sale.

    To learn more, visit petvivo.com or sprynghealth.com.

    Disclosure Information

    PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company's Investor Relations website, in addition to following the company's press releases, SEC filings, public conference calls, presentations and webcasts.

    Forward-Looking Commercial Statements

    The foregoing information regarding PetVivo Holdings, Inc. (the "Company") may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's proposed development and commercial timelines, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company's business are described in detail in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

    Company Contact

    John Lai, CEO

    PetVivo Holdings, Inc.

    Email Contact

    Tel (952) 405-6216

    PETVIVO HOLDINGS, INC.

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (UNAUDITED)

      For the Three Months Ended 
      June 30, 2025  June 30, 2024 
           
    Revenues $297,500  $123,751 
             
    Cost of Sales  110,774   12,994 
             
    Gross Profit  186,726   110,757 
             
    Operating Expenses:        
             
    Sales and Marketing  621,712   534,413 
    Research and Development  340,513   387,515 
    General and Administrative  1,068,818   1,233,261 
    Total Operating Expenses  2,031,043   2,155,189 
             
    Operating Loss  (1,844,317)  (2,044,432)
             
    Other Income (Expense)        
    Loss on Disposal of Assets  (149,125)  - 
    Unrealized Loss on Change in Derivative Liabilities  (320,404)  - 
    Other Income  111,518   - 
    Interest Income  13,099   - 
    Interest expense  (121,808)  (2,631)
    Total Other Income (Expense)  (466,720)  (2,631)
             
    Loss before taxes  (2,311,037)  (2,047,063)
             
    Income Tax Provision  -   - 
             
    Net Loss  (2,311,037)  (2,047,063)
     Less: Series B Preferred Stock Dividends  (28,603)   - 
    Net Loss Available to Common Stockholders $(2,339,640) $(2,047,063)
             
    Net Loss Per Share:        
    Basic and Diluted $(0.09) $(0.11)
             
    Weighted Average Common Shares Outstanding:        
    Basic and Diluted  24,302,790   18,683,975 



    See accompanying notes to these unaudited condensed consolidated financial statements.

    PETVIVO HOLDINGS, INC.

    CONSOLIDATED BALANCE SHEETS

    (UNAUDITED)

      June 30, 2025

    (Unaudited)
      March 31, 2025 
    Assets:        
    Current Assets        
    Cash $3,303,844  $227,689 
    Accounts receivable, net of allowance for credit losses  25,948   60,573 
    Subscriptions receivable  -   4,400,000 
    Inventory (Note 2)  529,342   323,504 
    Investments  150,000   150,000 
    Prepaid expenses and other assets (Note 3)  391,725   447,801 
    Total Current Assets  4,400,859   5,609,567 
             
    Property and Equipment, net (Note 4)  487,618   766,874 
             
    Other Assets:        
    Operating lease right-of-use  102,035   961,539 
    Patents and trademarks, net (Note 5)  22,494   23,725 
    Licensing Agreement, net (Note 6)  1,850,000   1,950,000 
    Security deposit  27,490   27,490 
    Total Other Assets  2,002,019   2,962,754 
    Total Assets $6,890,496  $9,339,195 
             
    Liabilities and Stockholders' Equity:        
             
    Current Liabilities        
    Accounts payable $744,392  $821,081 
    Accrued expenses (Note 7)  846,378   948,554 
    Operating lease liabilities – current portion  63,380   163,834 
    Notes payable and accrued interest – current portion (Note 8)  334,061   312,865 
    Convertible notes payable and accrued interest, net of discount of $790,631 and $149,644 (Note 9)  1,129,222   1,622,377 
    Derivative liabilities  -   448,089 
    Total Current Liabilities  3,117,433   4,316,800 
    Other Liabilities        
    Operating lease liabilities (net of current portion)  38,655   797,705 
    Notes payable and accrued interest (net of current portion) (Note 10)  3,431   5,442 
    Total Other Liabilities  42,086   803,147 
    Total Liabilities  3,159,519   5,119,947 
             
    Commitments and Contingencies (see Note 11)        
    Stockholders' Equity: (Note 13)        
    Preferred Stock, par value $0.001, 20,000,000 shares authorized:        
    Series A Preferred stock: 3,045,000 shares issued and outstanding at June 30, 2025 and March 31, 2025  3,045   3,045 
    Series B Preferred stock: 5,000,000 shares issued and outstanding at June 30, 2025 and March 31, 2025  5,000   5,000 
             
    Common Stock, par value $0.001, 250,000,000 shares authorized, 24,402,194 and 24,181,537 issued and outstanding at June 30, 2025 and March 31, 2025, respectively  24,402   24,182 
    Additional Paid-In Capital  97,236,660   95,385,511 
    Accumulated Deficit  (93,538,130)  (91,198,490)
    Total Stockholders' Equity  3,730,977   4,219,248 
    Total Liabilities and Stockholders' Equity $6,890,496  $9,339,195 



    See accompanying notes to these unaudited condensed consolidated financial statements.



    Primary Logo

    Get the next $PETV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PETV

    DatePrice TargetRatingAnalyst
    10/12/2021$7.00Buy
    ThinkEquity
    More analyst ratings

    $PETV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lai John bought $90,000 worth of shares (150,000 units at $0.60), increasing direct ownership by 13% to 1,288,592 units (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    4/17/24 5:28:07 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $PETV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Lai John was granted 84,375 shares (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    9/22/25 11:25:05 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Lowenthal Garry N was granted 79,375 shares (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    9/22/25 11:23:17 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Director Jasper Joseph William was granted 17,905 shares, increasing direct ownership by 26% to 87,659 units (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    8/11/25 6:15:19 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $PETV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $PETV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $PETV
    SEC Filings

    View All

    ThinkEquity initiated coverage on PetVivo Holdings with a new price target

    ThinkEquity initiated coverage of PetVivo Holdings with a rating of Buy and set a new price target of $7.00

    10/12/21 11:03:37 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PETVIVO HOLDINGS, INC. ANNOUNCES CLOSE OF NOTE CONVERSION AGREEMENTS TO EXTINGUISH OVER TWO MILLION DOLLARS OF OUTSTANDING DEBT

    MINNEAPOLIS, Sept. 30, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID: PETVW)) and its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively "PetVivo" or the "Company") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for horses, dogs and other companion animals announced today that the Company has recently entered into note conversion agreements ("Conversion Agreements") with four existing shareholders of the Company to convert the outstanding balances of fourteen promissory notes ("Notes") having an aggregate debt outstanding of $2,018,155 consisting of principal amount of $1.850,000, plus total accr

    9/30/25 11:33:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PetVivo Animal Health Expands Veterinary Education with New RACE-Approved CE Courses on Osteoarthritis and Regenerative Therapies

    On-demand programs deliver clinically relevant science, technical instruction, and case applications in small animal and equine practice MINNEAPOLIS, Sept. 25, 2025 (GLOBE NEWSWIRE) -- PetVivo Animal Health, a subsidiary of PetVivo Holdings, Inc. (OTCQX:PETV, OTCID: PETVW)) and a veterinary medical device company pioneering intra-articular and regenerative solutions, announces the launch of three new continuing education (CE) courses for veterinary professionals. Each RACE-approved program (1.0 credit hour) is designed to help veterinarians deepen their expertise in osteoarthritis (OA), joint injection techniques, and regenerative modalities for canine and equine patients. The courses -

    9/25/25 1:49:32 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing

    NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum, held September 18th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through September 23. Please schedule 1x1 meetings here September 18th PresentationTicker(s)Amplia Therapeutics Limited(OTC:INNMF, ASX: ATX))Kelyniam Global, Inc.(O

    9/18/25 8:35:00 AM ET
    $DRMA
    $INM
    $PETV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    PetVivo Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Entry into a Material Definitive Agreement

    8-K - PetVivo Holdings, Inc. (0001512922) (Filer)

    9/30/25 6:03:45 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by PetVivo Holdings Inc.

    SCHEDULE 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)

    7/28/25 10:47:08 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by PetVivo Holdings Inc.

    10-K - PetVivo Holdings, Inc. (0001512922) (Filer)

    7/10/25 5:06:51 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $PETV
    Leadership Updates

    Live Leadership Updates

    View All

    PetVivo and Commonwealth Partner to Advance Equine Wellness Across Thoroughbred Racing

    Minneapolis, MN, June 06, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, OTC:PETVW), an emerging biomedical device company focused on animal health, today announced a strategic collaboration with Commonwealth, the syndicated ownership group behind 2023 Kentucky Derby winner Mage, and 2022 Dubai World Cup Champion Country Grammer. The partnership centers on the clinical use and promotion of SPRYNG® with OsteoCushion® Technology, PetVivo's cutting-edge intra-articular device designed to support joint health and durability, and Precise PRP™, a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians in elite equine athletes. As part of t

    6/6/25 8:00:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PetVivo Engages Former Dechra North American President, Mike Eldred as Commercial and Operations Advisor

    PetVivo Board Appoints Eldred as Executive Director to Lead Company Product Commercialization and Operations MINNEAPOLIS, MN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW)), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Mike Eldred as the Company's Commercialization and Operations Advisor. His appointment as an Executive Director by the Company's Board of Directors draws upon Mr. Eldred's 30 years of executive experience in animal health and the veterinary industry to ramp up its product development and sales efforts. For the past 20 years, Mr. Eldred served as President of North American Operations for Dech

    1/27/25 9:29:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PetVivo Engages Another Top Sales Manager, Cindy Gill, for Regional Business Development Manager, as Adoption of Breakthrough Animal MedTech Device Continues to Spread Nationwide

    MINNEAPOLIS, MN, Oct. 21, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Cindy Gill to the position of field veterinary business development manager for the entire states of Oklahoma and Arkansas and the northern region of Texas. "Cindy's experience and strong record of sales achievement with veterinary clinics brings to our sales team a valuable resource for achieving our business goals," PetVivo CEO, John Lai. "Her experience with other veterinary products and her knowledge of clinic operations enables her to prioritize and better address the veterinarians and cli

    10/21/24 9:45:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $PETV
    Financials

    Live finance-specific insights

    View All

    PetVivo Reports Fiscal Q1 2026 Results

    MINNEAPOLIS, MN, US, Aug. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., including its wholly-owned subsidiary Petvivo Animal Health, Inc. (OTCQX:PETV, OTC ID: PETVW)), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, reported results for its first quarter of fiscal year 2026 ended June 30, 2025. All comparisons are to the previous year first quarter period ending June 30, 2024, unless otherwise noted. The company will hold a conference call today, August 14, 2025, at 5:00 p.m. Eastern time to discuss the results for the quarter, followed by a question-and-answer session (see dial-in information below). Fiscal Q1

    8/14/25 4:40:00 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PetVivo Sets Fiscal First Quarter 2026 Conference Call for Thursday, August 14, 2025 at 5:00 p.m. ET

    MINNEAPOLIS, MN, US, Aug. 07, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID: PETVW)), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, will hold a conference call on Thursday, August 14, 2025 at 5:00 p.m. Eastern time to discuss results for the fiscal first quarter ended June 30, 2025. The financial results will be issued in a press release prior to the call. PetVivo management will host the presentation, followed by a question-and-answer period. The Fiscal First Quarter 2026 conference call information is as follows: Date: Thursday, August 14, 2025 Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific t

    8/7/25 12:45:00 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PetVivo Reports Fiscal 2025 Results

    MINNEAPOLIS, MN, US, June 30, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. and its wholly-owned subsidiary PetVivo Animal Health, Inc. (OTCQB:PETV, OTC:PETVW), a leading biomedical company delivering innovative medical therapeutics for equines and companion animals, reported results for its fiscal year ended March 31, 2025. All comparisons are to the previous fiscal year period unless otherwise noted. The company has filed for an extension for the filing of its Form 10-K for the fiscal year ending March 31, 2025, therefore all financial results reported in this press release are unaudited preliminary estimates, and are subject to change. The company will hold a conference call today at

    6/30/25 4:10:00 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $PETV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PetVivo Holdings Inc.

    SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)

    11/19/24 3:38:53 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by PetVivo Holdings Inc.

    SC 13G - PetVivo Holdings, Inc. (0001512922) (Subject)

    11/4/24 1:57:37 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by PetVivo Holdings Inc.

    SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)

    10/1/24 5:26:09 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care